Information for Medical Professionals

Osteonecrosis could benefit from bone-marrow derived transplant

The transplantation of bone-marrow derived mononuclear cells (BMMNCs) to treat osteonecrosis of the femoral head could be beneficial in preventing collapse, it has been claimed.

According to research published in the Journal of Bone and Joint Surgery, while the recent study into BMMNCs used in conjunction with interconnected porous calcium hydroxyapatite (IP-CHA) was limited, the combination of the two appears to "confer benefit in the repair of osteonecrosis and in the prevention of collapse".

"A reduction in the size of the osteonecrotic lesion was observed subsequent to hypertrophy of the bone in the transition zone in the BMMNC group," the researchers said.

They looked at a total of 22 patients - and 30 hips - which underwent implantation of BMMNCs and a subsequent one-year follow up.

The results were compared to a control group of nine hips with osteonecrosis which were treated with cell-free IP-CHA.

Earlier research published in the European Journal of Bone and Joint Surgery showed that osteonecrosis was a determining factor in the development of secondary collapse following transtrochanteric rotational osteotomy of the femoral head.

---

<< Back

News provided by Adfero in collaboration with Biomet. Please note that all copy is (c) Adfero Ltd and does not reflect the views or opinions of Biomet unless explicitly stated.